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1. Introduction 
1.1 Ventilator associated pneumonia 
Ventilator associated pneumonia (VAP) is one of the sub-types of nosocomial acquired 
pneumonia occur in patients admitted to ICU who are under ventilator assistant mechanical 
ventilation occurring more than 48 h after patients have been intubated and received 
mechanical ventilation. Between 250,000 and 300,000 cases per year occur in the United 
States solely, which is an incidence rate of 5 to 10 cases per 1,000 hospital admissions1. The 
incidence of VAP increases with the duration of mechanical ventilation higher in day 10 
compare to day five2, and it is associated with high mortality rates (0-50%) in ICU patients, 
and pneumonia accounts for second cause of death in ICU patients3, although Using various 
scoring systems for the mortality prediction along with the guideline-based medicine have 
helped decrease in VAP mortality rates4,5. Although mortality of viral VAP is not 
determined in ICU patients, the scoring systems provide an acceptable clinical index for 
such cases [46]. The misuse of insufficient dose or inappropriate antibiotic will lead to 
outgrow multi drug resistant serotypes of bacterial VAP and induce higher mortality6. This 
high mortality rate also depends on the type of underlying disease, with highest mortality 
attributable to VAP in patients with trauma or acute respiratory distress syndrome7, and the 
type of organism affecting the patient. Higher mortality rates have been explored in VAP 
caused by Pseudomonas aeruginosa (in patients with underlying respiratory problems) 8, 
Acinetobacter, and Stenotrophomonas maltophilia than those associated with other organisms9. 
Bacterial VAP can be due to colonization and spread of organisms from oropharynx, sinus 
cavities, nares, dental plaque, gastrointestinal tract, patient-to-patient contact, and the 
ventilator circuit to the lungs10. Essentially, each ICU should have an established protocol in 
place to initial empirical therapy based on previously accepted guidelines modified by local 
knowledge of prevalence of resistant serotypes unique to that ICU. Notably, empiric 
therapy should be both appropriate by using more specific antibiotics and adequate by 
using correct dose and good penetration to the site of infection11. Duration of antibiotics are 
also been a point of controversy; although 8 days of therapy has been effective in non-
resistant organisem, but duration of antibiotic therapy for multiple drug resistant (MDR) 
organism such as P aeruginosa and Acinetobacter spp, is unknown12.  
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On the other hand, a key point in management of MDR VAP is rapid diagnosis of VAP 
and providing culture and anti-biogram in detecting the responsible organism. The 
antibiotic duration for patients with MDR VAP remains a controversial issue. Several 
serum biomarkers have been applied as potential biomarker contributing to guide 
antibiotic use in patients with VAP caused by MDR pathogens. Previously, pro-calcitonin 
(PCT) has been broadly used as a marker for community acquired pneumonia (CAP) and 
VAP13,14, however it does not incorporate into hospital acquired pneumonia(HAP). Using 
PCT has shortened duration of anti-microbial treatment in VAP15 in which patients with 
MDR VAP whose serum PCT concentrations are less than 0.5 ng/mL or decreased by 80% 
or more, compared with the first peak concentration, antibiotics may be terminated 3 days 
after initiation16. On the other hand usefulness of other bio-markers such as C reactive 
proteins(CRP) have yielded to conflicting data’s17, probably due to acute phase reactant 
release in ICU patients such as IL-6 and TNF-α which stimulate CRP release to 
surmountable amounts. 
Our current data on epidemiology, pathogenesis, clinical importance, and risk factors of 
viral VAP and viral pneumonia in ICU has many pitfalls due to some challenges18. First, 
the diagnosis of viral VAP in critically ill patients requires a high clinical suspicion 
combined with bedside examination, radiographic examination, and microbiologic 
analysis of respiratory secretions. Besides, the presence of indolent viral VAP in a 
critically ill patient makes diagnosis more challenging and increases the mortality rate of 
patients. It is important to investigate these viral markers in VAP to probe them earlier 
and estimate their role in increasing mortality rate. ICU patients assumed as 
immunocompetent are also at risk for Herpes simplex virus (HSV) and cytomegalovirus 
(CMV) VAP19.  Although CMV reactivation assumed to increase morbidities like 
increased length of stay in the ICU but impact on mortality particularly in patients with 
low CMV-DNA plasma levels is in doubt20. Currently there is increasing tendency to 
CMV infection among ICU patients. One simple explanation is that any bacterial 
colonization in ICU patients promotes the release of immunomodulatory cytokines and 
lead to reactivation of CMV21, and reactivation from the latency induces CMV infection. 
Because of nonspecific signs and symptoms ICU patients are rarely monitored routinely 
for active CMV infection, the development of active CMV infection could remain under-
diagnosed in critically ill patients.  
The 2009 H1N1 influenza virus pandemic has highlighted another challenge faced by 
intensivists in managing severe influenza A, especially for those at high risk of severe 
respiratory disease in ICUs44. Thus, intensivists should consider performing rapid 
diagnostic tests and specific scoring for drug resistance genotyping for high risk patients 
especially in tertiary care centers45. 
2. Hyperglycemia and hypoglycemia in ICU 
Essentially, ICU admitted patients encounter a profound hyperglycemia due to stress 
hormone surge, corticosteroid usage, and inhibition of insulin release of sepsis or trauma 
induced mediators22. Hyperglycemia could harm ICU patients by increase susceptibility 
to sepsis and increase mortality of critically ill patients23. It is supposed to have a tight 
control of hyperglycemia in ICU patients although threshold of blood glucose is still 
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controversial. As a matter of fact, glucose monitoring and rout of insulin injection is 
mainstay of hyperglycemia control in ICU patients. Nonetheless, different studies have 
suggested various blood glucose levels but majorly 180 mg/dl has considered the safe 
treatment threshold and 140-180 for target glucose level24,25,26,27,28. It is widely assumed 
that sampling in ICU patients could also be a bottleneck in glucose tight control as 
catheter sampling is easy but have danger of contamination with IV fluids, whether 
fingerprints sampling may be inaccurate in patients with edema or anemia29. On the other 
hand, insulin therapy induced hyperglycemia may cause severe neurologic damages 
while neurologic symptoms of hypoglycemia are difficult to detect in critically ill patients, 
but they are a real concern30. Severe hypoglycemia <40 mg/dl could occurred in almost 
high proportion of patients in intensive insulin therapy and could majorly increase 
mortality rates of patients31,32. Besides, all the studies with target glucose concentration of 
80 to 110 mg/dl showed increased rates of hypoglycemia33. Notably, even a blood glucose 
target of 180 mg/dl or less resulted in lower mortality than did a target of 81 to 108 
mg/dl34. 
3. Venous thromboembolism (VTE) and Pulmonary Embolism (PE) 
Venous thromboembolism(VTE) is a common and lethal complication in critically ill 
patients, due to several predisposing factors such as pre morbid conditions (e g, trauma, 
major surgeries, malignancy, sepsis), invasive interventions like central venous 
catheterization, and prolonged immobility35. The incidence of VTE is reported variously in 
different studies based on the population, prophylactic interventions and screening 
methods. Patients in intensive care unit have a higher risk of lower limb deep venous 
thrombosis (DVT) in comparison with other hospitalized patients which may be 
undiagnosed in considerable number of cases36. On the other hand, VTE could remain 
unrecognized in the intensive care unit because of the difficulty in eliciting signs and 
symptoms from intubated, sedated patients. It is likely that quite large number of patients 
under mechanical ventilation with unexpected episodes of tachycardia, hypotension, or 
hypoxia may have unnoticed pulmonary embolism (PE) 37 which could be diagnosed based 
on Geneva score with an acceptable predictive accuracy in low and intermediate-probability 
groups38.  Undiagnosed or barely suspected PE may also lead to delay weaning patients 
from mechanical ventilation. Intensive care unit patients, who have reduced 
cardiopulmonary reserve, are prone to have significant complications of PE. Recent data 
suggest that the duration of therapy and recurrence rate is associated with persistently 
elevated levels of d-dimer39. Long-term treatment of thrombosis with the low-molecular-
weight heparin has been shown to be associated with fewer thromboembolic recurrences in 
ICU patients40. 
4. Management of ICU-associated agitation by dexmedetomidine 
Agitated delirium is common complication occurs commonly in patients undergoing 
mechanical ventilation in ICU, and is often treated with haloperidol despite concerns 
about its adverse effects such as unpredictable hepatic toxicity and cardiotoxicity41. 
Inadequate sedation in ICU particularly in intubated patients adversely affects their 
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morbidity and mortality. Use of sedatives during agitation while patient under 
mechanical intubation precludes further extubation. Other than that agitation in intensive 
care may be associated with self-extubation, removal of vascular catheters, increased 
oxygen consumption and failure to cooperate with treatment. Drug of choice should be 
effective, safe, titrable, rapidly acting agent that has both sedative and analgesic activity, 
and could prevent anexiety and unpleasant memories. The newly introduced drug, 
Dexmedetomidine, a novel selective α2-agonist with sedative and anxiolytic properties, 
have showed particular utility in ICU-associated delirious agitated patients under 
mechanical ventilation without inducing excessive sedation, with fewer side effects than 
haloperidol, little interaction with other drugs and easily titrable. Studies have reported 
the successful use of dexmedetomidine in this context although multi-centric clinical trials 
may needed to establish those assumptions. Dexmedetomidine is more effective than 
conventional haloperidol therapy for the treatment of combined agitation and delirium in 
intubated patients in the ICU; besides Dexmedetomidine reduce the need of extra sedative 
known to cause agitation. Its administration superiority to traditional sedatives is reliably 
shown that has reduced ICU length of stay, hastened liberation from mechanical restraint, 
reduced the need for supplementary sedation, reduced QTc interval prolongation and 
possibly reduced the need for tracheostomy42. In a study in comparing dexmedetomidine 
and propofol in patients requiring sedation in ICU, dexmedetomidine revealed safer and 
protect against myocardial infarction43. In addition, some studies have proposed that 
patients who receive a dexmedetomidine bolous have no clinically significant 
hypotension or increased epinephrine requirement but others not. Dexmedetomidine 
induce no respiratory depression and should be considered for patient failing 
spontaneous breathing due to agitation or anxiety. On the other hand, in dose related 
hypotension and bradycardia bolus dexmedetomidine is not recommended. Besides, 
clinicians should consider higher starting dose of dexmedetomidine if used as 
monotherapy. 
 
 
Medication Dose Consideration 
Dexmedetomidine 0.2-1.5 mcg/kg/hr patients failing spontaneous breathing trials 
secondary to agitation 
Haloperidol 2.5-5mg IV q 15 min 
prn/ 2.5-5 mg PO q6 hr
Caution if baseline QTc >440 msec 
Aripiprazole 10-15 mg po daily Consider when baseline QTc>440 msec 
Quetiapine 50-200 mg po q12 hr Consider if sedative properties desired 
Risperidone 0.5-1 mg po q12 hr Caution baseline QTc >440 msec 
Propofol 1 mg/kg loding+1-
3mg/kg/h 
Consider vasodilation risk 
 
Table 1. Pharmacologic Treatment for Delirium. 
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